Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Maria M, Traczewski"'
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 30, Iss , Pp 96-99 (2022)
ABSTRACT: Objectives: Antibiotics are associated with increased risk of Clostridioides difficile infection, which has limited treatment options. We assessed in vitro activity of omadacycline (an aminomethylcycline antibiotic) against the C. difficile
Externí odkaz:
https://doaj.org/article/061fc20000c14acfb1c1d713fad6c482
Autor:
Gary W. Procop, Omai B. Garner, Sukantha Chandrasekaran, David H. Pincus, Simone Franklin, Deborah A. Wilson, Maria M. Traczewski, Denise Beasley, Hari P. Dwivedi, Marion J. Tuohy, Yohann Bala
Publikováno v:
Journal of clinical microbiology, vol 60, iss 1
The carbapenem/beta-lactamase inhibitor meropenem-vaborbactam (MEV) used to treat complicated urinary tract infections and pyelonephritis in adults was approved in 2017 by the U.S. Food and Drug Administration (FDA). Here, we evaluated Vitek 2 MEV (b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2fcb5a818104255ae741de61da0ed2
https://doi.org/10.1128/jcm.01610-21
https://doi.org/10.1128/jcm.01610-21
Autor:
Hari P, Dwivedi, Simone, Franklin, Sukantha, Chandrasekaran, Omai, Garner, Maria M, Traczewski, Denise, Beasley, Gary W, Procop, Marion, Tuohy, Deborah, Wilson, Yohann, Bala, David H, Pincus
Publikováno v:
J Clin Microbiol
The carbapenem/beta-lactamase inhibitor meropenem-vaborbactam (MEV) used to treat complicated urinary tract infections and pyelonephritis in adults was approved in 2017 by the U.S. Food and Drug Administration (FDA). Here, we evaluated Vitek 2 MEV (b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e3c904628e9c0cded52affe0c140d1fd
https://pubmed.ncbi.nlm.nih.gov/34705536
https://pubmed.ncbi.nlm.nih.gov/34705536
Autor:
Holly K. Huse, John J. LiPuma, Maria M. Traczewski, Peter Jorth, Mark J Lee, Susan E. Sharp, Mandy Wootton
Publikováno v:
J Clin Microbiol
The Burkholderia cepacia complex (BCC) is known for causing serious lung infections in people with cystic fibrosis (CF). These infections can require lung transplantation, eligibility for which may be guided by antimicrobial susceptibility testing (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eca82f6623f8e08bd377578de4b33ea
https://pubmed.ncbi.nlm.nih.gov/34524889
https://pubmed.ncbi.nlm.nih.gov/34524889
Publikováno v:
Journal of Cystic Fibrosis. 20:S207-S208
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51b685872e5e8c2df1ad067e914fe1db
https://doi.org/10.1016/s1569-1993(21)01864-6
https://doi.org/10.1016/s1569-1993(21)01864-6
Autor:
D. Celedonio, John J. LiPuma, Holly K. Huse, Peter Jorth, Maria M. Traczewski, A. Milesi Galdino
Publikováno v:
Journal of Cystic Fibrosis. 20:S214-S215
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79164f1591b272097c67ef63b1009c3e
https://doi.org/10.1016/s1569-1993(21)01878-6
https://doi.org/10.1016/s1569-1993(21)01878-6
Autor:
Omai B. Garner, Zabrina Lockett, Jennifer Chau, Christine Hastey, Regina Brookman, Maria M. Traczewski, Denise Beasley, Amanda Harrington, Sharon DesJarlais
Publikováno v:
Open Forum Infectious Diseases
Background Data from a multicenter clinical study with Enterobacterales, Salmonella spp. and P. aeruginosa on a MicroScan Dried Gram-negative MIC (MSDGN) Panel was evaluated with updated US FDA/CLSI levofloxacin breakpoints. MIC results were compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa8949051013fe7f8dd8b89beaf2cce1
http://europepmc.org/articles/PMC7776295
http://europepmc.org/articles/PMC7776295
Autor:
Shawn Vasoo, Meredith Hackel, Audrey N. Schuetz, Dan Sahm, Scott A. Cunningham, Elizabeth Palavecino, Stephen G. Jenkins, Efe Alyanak, Maria M. Traczewski, Christopher A. Gulvik, Robin Patel, Romney M. Humphries, Jayawant N. Mandrekar, Brandi Limbago, Karen Anderson, Adrian Lawsin, Tom J. B. de Man, Janet A. Hindler
Publikováno v:
Journal of Clinical Microbiology. 55:1954-1960
Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8a116d86d1ec92201f1ec9b66af228
https://doi.org/10.1128/jcm.00244-17
https://doi.org/10.1128/jcm.00244-17
Autor:
Michael D. Huband, Maria M. Traczewski, Patricia A. Bradford, Alita A. Miller, John P. Mueller
Publikováno v:
Journal of Clinical Microbiology. 57
This report describes the results of two different, multilaboratory quality control (QC) studies that were used to establish QC ranges for the novel gyrase inhibitor zoliflodacin against the ATCC strains recommended by the Clinical and Laboratory Sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0147d04fdd2d4a9f18923d73e61616c3
https://doi.org/10.1128/jcm.00567-19
https://doi.org/10.1128/jcm.00567-19
Autor:
Patricia Ruiz-Garbajosa, Andrew Dodgson, H Wang, Janet A. Hindler, Maria M. Traczewski, Romney M. Humphries, Rafael Cantón, A McEwan, Jennifer Veltman, Marta Tato
Publikováno v:
Journal of Clinical Microbiology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Rapid identification of patients who are colonized with carbapenemase-producing organisms (CPO) is included in multiple national guidelines for containment of these organisms. In a multisite study, we evaluated the performance of the Cepheid Xpert Ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf1f073da724cd82bab3b5442df0c2a9
https://doi.org/10.1128/jcm.00341-16
https://doi.org/10.1128/jcm.00341-16